Over at bbgm, Deepak Singh considers a slide that's been circulating which compares the number of approved New Molecular Entities to spending by members of PhRMA from 1970 to the early 2000s. Paul Kedrosky, who presented the slide recently, notes that "the mapping of the genome, and other such inflection points in this failure-prone industry, has done nothing to accelerate [new] drugs, while causing costs to escalate dramatically."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Penn State Hershey Medical Center staffer has admitted to lying about skipping mandatory steps of genetic cancer tests he performed, the Associated Press reports.

The genome of a rare, red bat suggests that its effective population size has been in decline for thousands of years, according to a PLOS One study.

In Nature this week: investigation into the genetics of medulloblastoma, and more.

A project in the UK is to use genomic selection to speed spruce tree growth, according to Innovators Magazine.